Ignite Creation Date:
2024-05-06 @ 2:13 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT01998126
Status:
COMPLETED
Last Update Posted:
2018-04-02
First Post:
2013-07-11
Brief Title:
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Sponsor:
Organization:
University of Utah